Viridian Therapeutics, Inc.\DE (VRDN) Change in Cash (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Change in Cash of -$36.0 million for Q1 2026, down 316.81% year-over-year from $16.6 million in Q1 2025, and down 184.32% quarter-over-quarter from $42.7 million in Q4 2025.
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Change in Cash (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Change in Cash history runs 14 years deep, the most recent figure standing at -$36.0 million for Q1 2026.
- In Q1 2026, Change in Cash fell 316.81% year-over-year to -$36.0 million; the TTM figure through Mar 2026 stood at $60.1 million (up 144.69% YoY), while the FY2025 annual figure was $112.8 million, up 3588.65% from the prior year.
- Change in Cash for Q1 2026 stood at -$36.0 million, down from $42.7 million in the prior quarter.
- The five-year high for Change in Cash was $312.9 million in Q3 2022, with the low at -$188.6 million in Q4 2022.
- The 5-year median for Change in Cash is $435000.0 (2022), against an average of $7.9 million.
- The sharpest annual moves came in 2022 and 2024: Change in Cash slumped 2032.6% in 2022, then soared 1218.35% in 2024.
- Viridian Therapeutics, Inc.\DE's Change in Cash stood at -$188.6 million in 2022, then jumped by 95.35% to -$8.8 million in 2023, then slumped by 1048.49% to -$100.7 million in 2024, then surged by 142.43% to $42.7 million in 2025, then tumbled by 184.32% to -$36.0 million in 2026.
- Business Quant data shows VRDN's Change in Cash at -$36.0 million in Q1 2026, $42.7 million in Q4 2025, and $52.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -185.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 374.50 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 427.25 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -2.94 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 225.59 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.42 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | -11.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -11.36 Mn |
| Mar 31, 2026 | -36.04 Mn |
| Dec 31, 2025 | 42.74 Mn |
| Sep 30, 2025 | 52.32 Mn |
| Jun 30, 2025 | 1.11 Mn |
| Mar 31, 2025 | 16.62 Mn |
| Dec 31, 2024 | -100.72 Mn |
| Sep 30, 2024 | 92.65 Mn |
| Jun 30, 2024 | 16.03 Mn |
| Mar 31, 2024 | -11.19 Mn |
| Dec 31, 2023 | -8.77 Mn |
| Sep 30, 2023 | 24.52 Mn |
| Jun 30, 2023 | -1.43 Mn |
| Mar 31, 2023 | -67.06 Mn |
| Dec 31, 2022 | -188.63 Mn |
| Sep 30, 2022 | 312.92 Mn |
| Jun 30, 2022 | 435,000.00 |
| Mar 31, 2022 | -11.44 Mn |
| Dec 31, 2021 | -96.58 Mn |
| Sep 30, 2021 | 111.17 Mn |